anaerobic dopamine (A-dopamine)
/ InBrain Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 16, 2025
DIVE-FOLLOW UP: Evaluation of Long-term Safety in Parkinsonian Patients With Intracerebroventricular Administration of A-dopamine (Anaerobic Dopamine)
(clinicaltrials.gov)
- P1/2 | N=1 | Recruiting | Sponsor: University Hospital, Lille
New P1/2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
September 22, 2025
InBrain Pharma to Present Long-Term Follow-Up Clinical Data from Its Phase I/II DIVE-I Trial in Parkinson’s Disease at the MDS 2025 Conference
(GlobeNewswire)
- "These long-term results confirm the excellent safety profile of the continuous intracerebroventricular infusion of A-dopamine in advanced parkinsonians refractory to L-dopa and also show a sustainable effect on motor control over time."
P1/2 data • Parkinson's Disease
1 to 2
Of
2
Go to page
1